Chromocell Therapeutics Files 8-K
Ticker: PTHS · Form: 8-K · Filed: 2024-08-07T00:00:00.000Z
Sentiment: neutral
Topics: 8-K, corporate-filing
TL;DR
Chromocell Therapeutics filed an 8-K on Aug 5, 2024. Check it out.
AI Summary
Chromocell Therapeutics Corporation filed an 8-K on August 7, 2024, reporting an event that occurred on August 5, 2024. The filing is categorized under 'Other Events' and 'Financial Statements and Exhibits'. The company is incorporated in Delaware and its principal executive office is located in Freehold, NJ.
Why It Matters
This filing indicates a corporate event or financial disclosure for Chromocell Therapeutics, requiring investor attention.
Risk Assessment
Risk Level: low — This is a routine filing and does not inherently indicate significant risk.
Key Numbers
- 001-41964 — Commission File Number (Identifies the company's SEC filing history)
- 86-3335449 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Chromocell Therapeutics Corporation (company) — Registrant
- August 5, 2024 (date) — Earliest event reported
- August 7, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Freehold, NJ (location) — Principal executive office
FAQ
What specific event is reported under 'Other Events' in this 8-K filing?
The filing does not specify the exact 'Other Event' in the provided text, only that it is categorized as such.
What is the primary business of Chromocell Therapeutics Corporation?
Based on the SIC code 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]', the company is involved in biological products.
When was the earliest event reported in this filing?
The earliest event reported was on August 5, 2024.
Where is Chromocell Therapeutics Corporation's principal executive office located?
The principal executive office is located at 4400 Route 9 South, Suite 1000, Freehold, NJ 07728.
What is the company's telephone number?
The company's telephone number, including area code, is (877) 265-8266.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-08-07 16:50:08
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share CHRO The NYSE American LL
- $250,000 — purchase Plan") pursuant to which up to $250,000 of the Company's common stock, par valu
Filing Documents
- g084379_8k.htm (8-K) — 27KB
- g084379_ex99-1.htm (EX-99.1) — 12KB
- 0001753926-24-001376.txt ( ) — 215KB
- chro-20240805.xsd (EX-101.SCH) — 3KB
- chro-20240805_lab.xml (EX-101.LAB) — 33KB
- chro-20240805_pre.xml (EX-101.PRE) — 22KB
- g084379_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On August 5, 2024, the board of directors of Chromocell Therapeutics Corporation (the "Company") authorized a stock repurchase plan (the "Repurchase Plan") pursuant to which up to $250,000 of the Company's common stock, par value, $0.0001 per share, may be repurchased prior to December 31, 2024, unless completed sooner or otherwise extended. Open market purchases are intended to be conducted in accordance with applicable Securities and Exchange Commission regulations, including the guidelines and conditions of Rule 10b-18 and Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The timing and actual number of shares repurchased will depend on a variety of factors including trading price, the Company's financial performance, corporate and regulatory requirements and other market conditions. A copy of the press release dated August 7, 2024 announcing the Repurchase Plan is filed as Exhibit 99.1, and incorporated by reference herein.
01
Item 9.01
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release dated August 7, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 7, 2024 CHROMOCELL THERAPEUTICS CORPORATION By: /s/ Francis Knuettel II Name: Francis Knuettel II Title: Chief Executive Officer and Chief Financial Officer